C. Boyer

Inhibition of cell growth by NB1011 requires high thymidylate synthase levels and correlates with p53, p21, bax, and GADD45 induction.

G. Wahl, H. Shepard, S. Neuteboom, 2002, Molecular cancer therapeutics.

A novel approach to thymidylate synthase as a target for cancer chemotherapy.

H. Shepard, J. Lee, C. Boyer, 2001, Molecular pharmacology.

Enzyme-catalyzed therapeutic agent (ECTA) design: activation of the antitumor ECTA compound NB1011 by thymidylate synthase.

R. Stroud, H. Shepard, M. Beryt, 2001, Biochemical pharmacology.

Nucleoside transport inhibitors, dipyridamole and p-nitrobenzylthioinosine, selectively potentiate the antitumor activity of NB1011

G. Wahl, S. Neuteboom, M. Pegram, 2002, Anti-cancer drugs.

SYNTHESIS AND BIOLOGICAL EVALUATION OF BORONATED NUCLEOSIDES FOR BORON NEUTRON CAPTURE THERAPY (BNCT) OF CANCER

S. Eriksson, G. Morrison, S. Chandra, 2001, Nucleosides, nucleotides & nucleic acids.